Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – More >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 1.90 (3.41%)
Intraday High$57.72
Intraday Low$55.98
Data as of 12/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
11/19/14Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
Clovis’ “BRCAness” DNA signature predicts which patients respond to rucaparib therapy Overall response rate (ORR) of 70% in BRCA-mutant patients; responses observed in patients with both germline and somatic mutations ORR of 40% in patients with BRCAness signature (all BRCA wild-type) ORR of only 8% in patients without BRCAness signature (all BRCA wild-type) Approximately ... 
Printer Friendly VersionDownload PDF
11/18/14Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
67% objective response rate (ORR) observed in evaluable heavily-pretreated T790M+ patients treated with 625mg or 500mg BID (clinical dose group) Median PFS of 10.4 months in clinical dose group; data continue to mature Well-tolerated – majority of treatment-related adverse events are grade 1-2 In T790M-negative patients treated with 625mg or 500mg BID, 36% ORR and median PFS of... 
Printer Friendly VersionDownload PDF
11/17/14Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
Study to evaluate the combination of rociletinib (CO-1686) with trametinib for patients with advanced or metastatic mutant EGFR NSCLC BOULDER, Colo.--(BUSINESS WIRE)--Nov. 17, 2014-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). T... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.